ABSTRACT
BACKGROUND: Although there is extensive literature on the clinical benefits of COVID-19 vaccination, data on humanistic effects are limited. This study evaluated the impact of SARS-CoV-2 infection on symptoms, Health-Related Quality of Life (HRQoL) and Work Productivity and Impairment (WPAI) prior to and one month following infection between individuals vaccinated with BNT162b2 and those unvaccinated. METHODS: Subjects with ≥ 1 self-reported symptom and positive RT-PCR for SARS-CoV-2 at CVS Health US test sites were recruited between 01/31/2022 and 04/30/2022. Socio-demographics, clinical characteristics and vaccination status were evaluated. Self-reported symptoms, HRQoL, and WPAI outcomes were assessed using questionnaires and validated instruments (EQ-5D-5L, WPAI-GH) across acute COVID time points from pre-COVID to Week 4, and between vaccination groups. Mixed models for repeated measures were conducted for multivariable analyses, adjusting for several covariates. Effect size (ES) of Cohen's d was calculated to quantify the magnitude of outcome changes within and between vaccination groups. RESULTS: The study population included 430 subjects: 197 unvaccinated and 233 vaccinated with BNT162b2. Mean (SD) age was 42.4 years (14.3), 76.0% were female, 38.8% reported prior infection and 24.2% at least one comorbidity. Statistically significant differences in outcomes were observed compared with baseline and between groups. The EQ-Visual analogue scale scores and Utility Index dropped in both cohorts at Day 3 and increased by Week 4 but did not return to pre-COVID levels. The mean changes were statistically lower in the BNT162b2 cohort at Day 3 and Week 4. The BNT162b2 cohort reported lower prevalence and fewer symptoms at index date and Week 4. At Week 1, COVID-19 had a large impact on all WPAI-GH domains: the work productivity time loss among unvaccinated and vaccinated was 65.0% and 53.8%, and the mean activity impairment was 50.2% and 43.9%, respectively. Except for absenteeism at Week 4, the BNT162b2 cohort was associated with statistically significant less worsening in all WPAI-GH scores at both Week 1 and 4. CONCLUSIONS: COVID-19 negatively impacted HRQoL and work productivity among mildly symptomatic outpatients. Compared with unvaccinated, those vaccinated with BNT162b2 were less impacted by COVID-19 infection and recovered faster.
ABSTRACT
Introduction: The COVID-19 pandemic presented challenges around disease management, lifestyle changes, and provision of care for patients (pts) with ulcerative colitis (UC). The survey aimed to understand how the COVID-19 pandemic impacted pts with UC and assessed overall disease management, telehealth use, healthcare experience, perceived quality of care, emotional well-being, reliance on alternative support systems, and preferences for virtual/in-person interactions with doctors. Disease management before, during, and after the COVID-19 pandemic: reliance on alternative support systems for management of ulcerative colitis Prior to the pandemic During the pandemic Plan to do after the pandemic Have never done or plan to do Talked openly with their doctor about how their disease impacts their life 54% 54% 44% 17% Set goals with their doctor for managing their disease 48% 46% 40% 25% Communicated with a nurse at their doctor’s office between appointments 45% 40% 34% 32% Used an online patient portal to contact their doctor’s office or see lab results 31% 47% 33% 32% Used social media to connect with other patients or learn about ulcerative colitis 24% 39% 27% 46% Used symptom tracking or disease management apps 23% 31% 29% 48% Relied on information from patient advocacy groups 19% 27% 22% 54% Relied on patient support groups 15% 22% 22% 59% Had virtual appointments with their doctor 13% 55% 32% 31%